Christopher K. Mirabelli, PhD
President, DecImmune and Managing Director, HealthCare Ventures
Dr. Mirabelli joined HealthCare Ventures in 2000 and is a Managing Director at the firm. Dr. Mirabelli was Chairman of the Board and Chief Executive Officer of LeukoSite, Inc. from 1993 through 1999, a company in which HealthCare Ventures was the lead investor. Dr. Mirabelli was also a co-founder of Isis Pharmaceuticals and served with SmithKline and French Laboratories R&D Division. Dr. Mirabelli received his doctorate in molecular pharmacology from Baylor College of Medicine.
Walter Newman, PhD
Chief Scientific Officer
Dr. Newman, a graduate of Columbia University’s undergraduate and graduate programs with a degree in immunology, led drug discovery at LeukoSite and Critical Therapeutics where he helped bring multiple antibody and small molecule candidates into clinical trials. LeukoSite’s efforts resulted in two approved monoclonal therapeutics, alemtuzumab and vedolizumab. In addition he was the founding CSO at Proteostasis Therapeutics. Prior to that, Dr Newman had senior roles in drug discovery at both Ortho Pharmaceuticals and Otsuka America Pharmaceuticals, subsequent to an academic career at the Fred Hutchinson Cancer Research Center. He has co-authored over eighty scientific articles in peer-reviewed journals.
Mr. Hoey brings more than 20 years of executive-level experience in business development, licensing, strategic planning, and financing for technology companies. He has completed over $400 million in corporate partnering transactions and equity financings in the United States, Europe, and Japan and has secured extensive contracts for government sponsored research.